DAmico_risk_classification_prostate_cancer v.1
D'Amico Risk Classification for Prostate Cancer assesses 5 year risk of treatment failure based on clinical factors.
Assesses 5 year risk of treatment failure based on clinical factors.
Developed in 1998, estimates risk of prostate cancer recurrence (low, medium or high) from PSA level, Gleason Score, and tumor stage. May be less accurate in men with multiple risk factors. Low risk: Gleason Score < 6 and PSA < 10 ng/ml and Clinical stage T1c or T2a Intermediate risk: Gleason Score of 7 or PSA of 10-20 ng/ml Clinical stage T2b High risk: Gleason Score > 8 or PSA > 20 ng/ml or Clinical stage T2c or T3
1. D'Amico AV, Whittington R, Malkowicz S, et al. Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer. JAMA.1998;280(11):969-974. doi:10.1001/jama.280.11.969.
OBSERVATION.lab_test_psa.v1, OBSERVATION.prostate_cancer_tnm_staging.v1, EVALUATION.damico_risk_classification_prostate_cancer.v0
